

**Dear Iowa State Medicaid Review Board for Tardive Dyskinesia (TD):**

**It has come to my attention that the criteria for Medicaid coverage will be possibly changing to Ingrezza being used as a third line medication for the treatment of Tardive Dyskinesia and this concerns me. I have had recent success with Ingrezza with many of my patients.**

**The last two times Ingrezza has been up for vote to raise in tier, it has been turned down and remains the preferred agent. This is important to note because Ingrezza is precisely focused on the treatment of TD. The proposal that will be reviewed in November will put Ingrezza as a third tier choice for insurance companies putting Tetrabenazine and Austedo as the new preferred generic and brand agents respectively. Neither one of these medications specifically target TD. They come with a black box warning for "depression and suicidality" and may not be appropriate for patients with a history of depression. Working in the mental health industry, many of our patients struggle with depression in conjunction with TD, making Ingrezza the best option for these patients.**

**With this reasoning it is my strong opinion that Ingrezza remain the preferred agent in the treatment of Tardive Dyskinesia. If I can help in any way please contact me at [REDACTED]**